Cargando…

Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN(®) (0.19 mg fluocinolone acetonide implant)

INTRODUCTION: The Retro-IDEAL (ILUVIEN Implant for chronic DiabEtic MAcuLar edema) study is a retrospective study designed to assess real-world outcomes achieved with the ILUVIEN® (0.19 mg fluocinolone acetonide (FAc)) in patients with chronic diabetic macular edema (DME) in clinical practices in Ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Augustin, Albert J, Bopp, Silvia, Fechner, Martin, Holz, Frank, Sandner, Dirk, Winkgen, Andrea-M, Khoramnia, Ramin, Neuhann, Thomas, Warscher, Marcus, Spitzer, Martin, Sekundo, Walter, Seitz, Berthold, Duncker, Tobias, Ksinsik, Christian, Höh, Helmuth, Gentsch, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079293/ https://www.ncbi.nlm.nih.gov/pubmed/30884972 http://dx.doi.org/10.1177/1120672119834474

Ejemplares similares

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2020)

Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)—results from the ILUVIT study
por: Deuchler, Svenja K., et al.
Publicado: (2022)

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
por: Hikal, Muaas, et al.
Publicado: (2021)

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
por: Moll-Udina, Aina, et al.
Publicado: (2023)

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy
por: Lima-Fontes, Mário, et al.
Publicado: (2022)

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study
por: Khoramnia, Ramin, et al.
Publicado: (2023)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
por: Kessler, Lucy Joanne, et al.
Publicado: (2022)

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
por: Weber, Lea F., et al.
Publicado: (2019)

A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber
por: El-Ghrably, Ibraheem A., et al.
Publicado: (2015)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023)

Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
por: Kessler, Lucy Joanne, et al.
Publicado: (2023)

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
por: Elbarky, Ahmed Mohammed
Publicado: (2020)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule
por: Alzaabi, Manal, et al.
Publicado: (2020)

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020)

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN(®))
por: Bodaghi, Bahram, et al.
Publicado: (2020)

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
por: Alfaqawi, Fadi, et al.
Publicado: (2018)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide)
por: Butt, Farhat, et al.
Publicado: (2016)

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
por: Bailey, C, et al.
Publicado: (2017)

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
por: McCluskey, Jessica D, et al.
Publicado: (2019)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review
por: Ribeiro, Flávio, et al.
Publicado: (2021)

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy
por: Meireles, A, et al.
Publicado: (2017)

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome
por: Marques, João Heitor, et al.
Publicado: (2021)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
por: Coelho, João, et al.
Publicado: (2019)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
por: Young, James F., et al.
Publicado: (2019)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien(®)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon, Habiba, et al.
Publicado: (2017)

Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN(®) clinical evidence study in Portugal
por: Carneiro, Angela, et al.
Publicado: (2020)

Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
por: Bailey, Clare, et al.
Publicado: (2021)

Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve
por: Battista, Marco, et al.
Publicado: (2021)

Real-Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation
por: Quhill, Hibba, et al.
Publicado: (2016)

Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema
por: El Rayes, Ehab N., et al.
Publicado: (2023)

Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema
por: Minnella, Angelo Maria, et al.
Publicado: (2021)

Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study
por: Buhl, Lara, et al.
Publicado: (2022)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations
por: Adán, Alfredo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oql07n99lp6hf92sfdfhivoc17